Payment overview · 2025
General Payments
$2,948.81
145 reported records · 25 companies
Healthcare provider profile · identity verified
Eric Paul Benson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · POST FALLS, ID · NPI 1639272644
Verified facts
What the public records show
CMS Open Payments records show Eric Paul Benson, MD received $2,948.81 in general payments during 2025 across 145 reported records.
GlaxoSmithKline, LLC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Qulipta, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucynta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $463.58 | 15.7% | 29 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $385.94 | 13.1% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $378.61 | 12.8% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $233.78 | 7.9% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $229.87 | 7.8% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $192.83 | 6.5% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $187.78 | 6.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $186.17 | 6.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.58 | 4.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.48 | 3.4% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.59 | 1.8% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $51.51 | 1.8% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $42.21 | 1.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $39.74 | 1.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.75 | 1.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.07 | 1.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.11 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.65 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.63 | 0.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.04 | 0.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $20.69 | 0.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.81 | 0.7% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.51 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.06 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.82 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,948.81 | 145 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $403.65 | 26 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $385.94 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $343.91 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $270.96 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $187.39 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $186.17 | 8 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $155.26 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $127.73 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $127.73 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $115.61 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.61 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.48 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $92.40 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $77.65 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $77.22 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $74.61 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $59.93 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.59 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $51.51 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
140 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 402 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 87 |
| Omeprazole | Omeprazole | 260 | 74 |
| Lisinopril | Lisinopril | 249 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 243 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 237 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 24 |
| Trazodone Hcl | Trazodone Hcl | 164 | 48 |
| Gabapentin | Gabapentin | 162 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 154 | 42 |
| Losartan Potassium | Losartan Potassium | 153 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 39 |
| Tramadol Hcl | Tramadol Hcl | 144 | 31 |
| Alprazolam | Alprazolam | 142 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 140 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 36 |
| Xarelto | Rivaroxaban | 129 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 124 | 15 |
| Potassium Chloride | Potassium Chloride | 116 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 31 |
| Carvedilol | Carvedilol | 102 | 28 |
| Pregabalin | Pregabalin | 97 | 13 |
| Eszopiclone | Eszopiclone | 95 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 23 |
| Metformin Hcl | Metformin Hcl | 88 | 29 |
| Clonazepam | Clonazepam | 80 | 14 |
| Furosemide | Furosemide | 79 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 23 |
| Buspirone Hcl | Buspirone Hcl | 72 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Eliquis | Apixaban | 70 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 18 |
| Simvastatin | Simvastatin | 68 | 19 |
| Lorazepam | Lorazepam | 66 | 13 |
| Ozempic | Semaglutide | 66 | 14 |
| Prednisone | Prednisone | 65 | 32 |
| Synthroid | Levothyroxine Sodium | 62 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Irbesartan | Irbesartan | 61 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 14 |
| Bupropion Xl | Bupropion Hcl | 60 | 14 |
| Mounjaro | Tirzepatide | 60 | 13 |
| Allopurinol | Allopurinol | 59 | 19 |
| Spironolactone | Spironolactone | 57 | 15 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Estradiol | Estradiol | 48 | 13 |
| Nifedipine Er | Nifedipine | 46 | 12 |
| Meloxicam | Meloxicam | 45 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 11 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 20 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 17 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,948.81 · 145 records | GlaxoSmithKline, LLC. | AJOVY, AUSTEDO XR, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, Hillrom - Vest System Model 105 Home Care, ISTURISA, Kerendia, Korlym, LEQVIO, MOUNJARO, NUCALA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, WATCHMAN FLX, XIFAXAN, XTAMPZA, XYOSTED, YUPELRI, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error